UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 600

Sortiert nach

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

The Lancet (British edition), 2014-06, Vol.383 (9936), p.2213-2221

2014

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29

PLoS medicine, 2017-07, Vol.14 (7), p.e1002346

2017

Link zum Volltext

Verfügbarkeit prüfen

Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study

BMJ open, 2021-06, Vol.11 (6), p.e048788-e048788

2021

Link zum Volltext

Verfügbarkeit prüfen

Hyperacute stroke thrombolysis via telemedicine: a multicentre study of performance, safety and clinical efficacy

BMJ open, 2022-01, Vol.12 (1), p.e057372-e057372

2022

Link zum Volltext

Verfügbarkeit prüfen

Carbon dioxide flushing versus saline flushing of thoracic aortic stents (INTERCEPTevar): protocol for a multicentre pilot randomised controlled trial

BMJ open, 2023-04, Vol.13 (4), p.e067605-e067605

2023

Link zum Volltext

Verfügbarkeit prüfen

Anticholinergics for urinary symptoms in multiple sclerosis

Cochrane database of systematic reviews, 2009-01 (1), p.CD004193

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

BMJ open, 2024-02, Vol.14 (2), p.e083582-e083582

2024

Link zum Volltext

Verfügbarkeit prüfen

OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis

BMJ open, 2021-11, Vol.11 (11), p.e050176-e050176

2021

Link zum Volltext

Verfügbarkeit prüfen

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

The Lancet (British edition), 2018-03, Vol.391 (10127), p.1263-1273

2018

Link zum Volltext

Verfügbarkeit prüfen

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

Current medical research and opinion, 2020-07, Vol.36 (7), p.1157-1166

2020

Link zum Volltext

Verfügbarkeit prüfen

The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis

Current medical research and opinion, 2020-07, Vol.36 (7), p.1145-1156

2020

Link zum Volltext

Verfügbarkeit prüfen

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

The New England journal of medicine, 2012-09, Vol.367 (12), p.1098-1107

2012

Link zum Volltext

Verfügbarkeit prüfen

Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility

Journal of medical economics, 2017-09, Vol.20 (9), p.962-973

2017

Link zum Volltext

Verfügbarkeit prüfen

Primary care family physicians and 2 hospitalist models: comparison of outcomes, processes, and costs

The Journal of family practice, 2002-12, Vol.51 (12), p.1021-1027

2002

Link zum Volltext

Verfügbarkeit prüfen

A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

Journal of medical economics, 2017-05, Vol.20 (5), p.474-482

2017

Link zum Volltext

Verfügbarkeit prüfen

Are frequent callers to family physicians high utilizers?

Annals of family medicine, 2004-11, Vol.2 (6), p.546-548

2004

Link zum Volltext

Verfügbarkeit prüfen

Low-molecular-weight heparin in preventing and treating DVT

American family physician, 1999-03, Vol.59 (6), p.1607-1612

1999

Link zum Volltext

Verfügbarkeit prüfen

Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions

The Journal of family practice, 1996-01, Vol.42 (1), p.69-78

1996

Link zum Volltext

Verfügbarkeit prüfen

Intussusception

American family physician, 1996-07, Vol.54 (1), p.213

1996

Link zum Volltext

Verfügbarkeit prüfen

How should we manage infants at risk for group B streptococcal disease? (Clinical Inquiries: from the Family Practice Inquiries Network)

The Journal of family practice, 2003-05, Vol.52 (5), p.406

2003

Link zum Volltext

Verfügbarkeit prüfen

Drug samples: benefit or bait?

JAMA : the journal of the American Medical Association, 1998-06, Vol.279 (21), p.1698

Wolf, B L

1998

Link zum Volltext

Verfügbarkeit prüfen

High-altitude syncope: history repeats itself

JAMA : the journal of the American Medical Association, 1993-02, Vol.269 (5), p.587

Perrill, C V

1993

Link zum Volltext

Verfügbarkeit prüfen

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

The Lancet (British edition), 2021-09, Vol.398 (10303), p.843-855

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 600

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

ThemaGeneral & Internal Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(583)
Mit Volltextzugriff
(503)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29

Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study

Hyperacute stroke thrombolysis via telemedicine: a multicentre study of performance, safety and clinical efficacy

Carbon dioxide flushing versus saline flushing of thoracic aortic stents (INTERCEPTevar): protocol for a multicentre pilot randomised controlled trial

Anticholinergics for urinary symptoms in multiple sclerosis

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility

Primary care family physicians and 2 hospitalist models: comparison of outcomes, processes, and costs

A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis

Are frequent callers to family physicians high utilizers?

Low-molecular-weight heparin in preventing and treating DVT

Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions

Intussusception

How should we manage infants at risk for group B streptococcal disease? (Clinical Inquiries: from the Family Practice Inquiries Network)

Drug samples: benefit or bait?

High-altitude syncope: history repeats itself

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis

Aktive Filter

Suchergebnisse filtern